Emerging evidence implicates KDM5A in human cancer pathogenesis, specifically via promotion of cell proliferation, repression of tumor suppressor gene expression, and development of drug tolerance.85 We believe that KDM5A inhibition is an excellent novel candidate for RB-negative OS therapy. The gene discussed is RB1; the disease is cancer.